CMAC appoints new Industry Director

A University of Strathclyde-led consortium which accelerates progress in pharmaceutical development and manufacturing has appointed a new Industry Director.

Massimo Bresciani has taken up the post with CMAC (Continuous Manufacturing and Advanced Crystallisation), which accelerates the adoption of advanced manufacturing solutions for the design, development and production of high-value pharmaceutical products.

He will provide leadership to CMAC’s industry engagement, knowledge exchange and research translation activities for industry and academic partners across major programmes, including the flagship EPSRC Future Manufacturing Research Hub.

Mr Bresciani has gathered a wealth of experience from his career, spanning many years in industry, and has most recently worked in a senior role at the academic-industry interface. He began his career working in a drug delivery company, specialising in bioenhancement and controlled release systems, and has held positions in specialty pharma and multinational pharma, as well as Contract Development and Manufacturing Organisations (CDMOs).

Massimo Bresciani. Photo by Pierpaolo Turri

Mr Bresciani said: “It is an honour to be joining CMAC’s leadership team and offer my experience and drive to deliver the impact from its innovative and disruptive programmes aimed to build value for patients via the implementation of new pharmaceutical science solutions. I am really excited about this new opportunity to deliver value for our partners and look forward to taking up the role.’’

CMAC Director Professor Alastair Florence said: “I am delighted to welcome Massimo to CMAC and look forward to working with him to deliver the next phase of our growth as a Global Research Hub for advanced pharmaceutical manufacturing research, translation and skills development.”

Dr Jon-Paul Sherlock, CMAC Industry Board Chair, said: “The translation of the excellent research at CMAC into industrial impact is a priority for the Industry Board. I look forward to working with Massimo, to build on what is already a strength for CMAC, to deliver new approaches that accelerate translation and maximise value for partners.”

Mr Bresciani has substantial expertise in the development of New Chemical Entities, from lead optimisation and candidate selection throughout preclinical and clinical phases to proof of concept and beyond, encompassing the ‘bench to bedside’ translational paradigm and biopharmaceutics.

Track record

He also has a proven track record of growing successful relationships, working with business leaders and developing international consortia. In addition, he has active interests in patient-centricity and personalised medicine and is an executive board member of the Geriatric Medicine Society.

CMAC, now in its 10th year, is based in Strathclyde’s Technology and Innovation Centre and has attracted more than £50 million of investment to date. These investments have established a world-class research facility supporting a portfolio of training, research and translation programmes developed in partnership with industry to transform the way medicines are developed and manufactured. The facility is sited in the Glasgow City Innovation District, which is transforming the way academia, business and industry collaborate to bring competitive advantage to Scotland.

The University of Strathclyde is a strategic partner in the new Medicines Manufacturing Innovation Centre (MMIC) and CMAC is working closely with MMIC to develop novel digital design tools for drug product manufacture using continuous direct compression.